The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Check out the companies making headlines in midday trading:
Johnson & Johnson — Shares of the pharmaceutical and consumer goods company fell more than 5% after Bloomberg News reported that the U.S. Justice Department is launching a criminal investigation into whether or not the company lied to the public about potential cancer risks in its talcum baby powder. The reported probe comes after thousands of cancer patients launched a civil suit claiming that asbestos in J&J's talc was responsible for their disease.
Milacron Holdings — Shares of the plastics-processing equipment maker surged 23% Friday after it agreed to be bought by industrial equipment maker Hillenbrand. The cash and stock deal is valued at roughly $2 billion, according to the companies, and represents a 34% to where Milacron closed on Thursday. Hillenbrand shares meanwhile dropped 10%.
Apellis Pharmaceuticals — The clinical-stage biopharmaceutical company jumped more than 4% after it was upgraded to overweight from neutral by J.P. Morgan Friday. The bank's analyst highlighted opportunities in a later stage blood disease drug and said the asset was underappreciated.
Illumina — Shares of the biotech company dropped more than 16% Friday after reporting disappointing revenue. Illumina said it sees sales coming in around $835 million for the quarter, versus the $887.9 million in revenue analysts polled by Refinitiv were expecting.
Stitch Fix — The online personal styling service's stock jumped 1% after Goldman Sachs upgraded to buy from neutral. According to the analyst, the company is expected to outperform due to "product innovation, operational efﬁciencies, and geographic expansion, combined with the increase in retail store closures (particularly in apparel)." Shares later closed nearly 2% lower.
Merck & Co — The pharmaceutical company closed Friday down 1.6% following an announcement yesterday from the White House that the Trump administration was abandoning a proposal which would have gotten rid of rebates from government drug plans.
Lincoln Electric Holdings — Shares of the manufacturer of welding products rose 3.5% after R.W. Baird upgraded the to outperform from neutral, citing a drop in input costs and low expectations, among other things.
— CNBC's Mallika Mitra contributed to this report and Elizabeth Myong contributed to this report.